Mallinckrodt's higher-dose Pennsaid gets 2nd FDA look, as firm faces lawsuit
This article was originally published in Scrip
A day after Mallinckrodt Pharmaceuticals' partner filed a lawsuit in the US District Court for the Southern District of New York against the firm asserting breach of contract involving its Pennsaid (diclofenac sodium topical solution) products, the company said the FDA had accepted its resubmitted new drug application (NDA) for the 2% formulation of the non-steroidal anti-inflammatory drug, which previously went under the moniker MNK-395.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.